Millennium Management LLC Sells 734,688 Shares of Encompass Health Co. (NYSE:EHC)

Millennium Management LLC lowered its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 91.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,623 shares of the company's stock after selling 734,688 shares during the quarter. Millennium Management LLC owned about 0.07% of Encompass Health worth $6,153,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of EHC. Vanguard Group Inc. lifted its holdings in Encompass Health by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock valued at $960,817,000 after acquiring an additional 138,196 shares during the last quarter. Invesco Ltd. lifted its holdings in Encompass Health by 3.3% in the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after acquiring an additional 176,135 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Encompass Health by 6.0% in the 4th quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock valued at $191,799,000 after acquiring an additional 117,617 shares during the last quarter. FMR LLC lifted its holdings in Encompass Health by 0.8% in the 4th quarter. FMR LLC now owns 1,973,846 shares of the company's stock valued at $182,285,000 after acquiring an additional 15,831 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Encompass Health by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company's stock valued at $155,176,000 after acquiring an additional 6,164 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Insider Transactions at Encompass Health

In other news, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the transaction, the executive vice president now owns 79,710 shares of the company's stock, valued at $9,149,910.90. This trade represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 132,663 shares of company stock valued at $16,034,082 over the last three months. 2.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Barclays upped their price target on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Royal Bank of Canada upped their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. KeyCorp upped their price objective on shares of Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. UBS Group upped their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. Finally, William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Encompass Health presently has a consensus rating of "Buy" and a consensus price target of $122.71.

Encompass Health Stock Up 0.8%

Shares of NYSE EHC traded up $1.00 during mid-day trading on Friday, reaching $121.01. The company had a trading volume of 977,100 shares, compared to its average volume of 702,178. The stock has a fifty day moving average of $109.93 and a two-hundred day moving average of $102.01. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The company has a market capitalization of $12.20 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a 12-month low of $82.74 and a 12-month high of $122.09.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm's revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 earnings per share. As a group, equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio (DPR) is 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.